Rituxan Injection, Solution
Product Images NDC 50242-053

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rituxan (NDC 50242-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rituxan 01)

A Kaplan-Meier survival curve graph illustrating progression-free survival probability over time in months. The graph compares two treatment groups, Observation (solid red line) and Rituxan (dashed blue line), with survival probabilities on the vertical axis and time on the horizontal axis. Below the graph is a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 2 (Rituxan 02)

A line graph showing the percent of ACR 20 responders over 24 weeks, comparing Rituxan 2x1000mg (n=298) and placebo (n=201). The vertical axis represents percent ACR 20 responders, ranging from 0 to 100, and the horizontal axis represents time in weeks from 0 to 24. Rituxan responders show an increase and are consistently higher than placebo throughout the study period.*

FDA Label Image

Figure 3 (Rituxan 03)

A Kaplan-Meier survival curve chart comparing the percentage of patients with first major relapse over 28 months for Azathioprine versus Rituximab. The azathioprine group is represented by a red dashed line showing higher relapse rates, while the rituximab group is shown with a solid blue line indicating lower relapse rates. Tables below the chart display the number of subjects with major relapse and those at risk for each treatment over time.*

FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Label for Rituxan (rituximab) injection, intravenous use, strength 10 mg/mL in a 100 mg/10 mL vial. The label includes the NDC number 50242-051-21 and states the product is prescription only. It is jointly marketed by Biogen and Genentech USA, Inc.*

FDA Label Image

Principal Display Panel (500 mg Vial Carton)

Rituxan (rituximab) injection label showing 500 mg/50 mL (10 mg/mL) strength for intravenous use. The label states the product is for prescription use only and is jointly marketed by Biogen and Genentech USA, Inc. It includes the NDC 50242-053-06 and depicts one 500 mg vial.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.